Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Rifaximin anti-rectal dysfunction preparation

A rifaximin and rectal technology, applied in the field of rifaximin anti-rectal dysfunction preparations, can solve problems such as shortening the healing time, increasing sensitivity, and finding no antibiotics

Inactive Publication Date: 2009-12-02
SALIX PHARMA INC
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, none of these formulations have conclusively been shown to shorten healing time or reliably reduce associated pain, and some of these treatments, such as Neosporin ointment, are very sensitizing
Additionally, antibiotics have not been found to be useful in the treatment of these diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rifaximin anti-rectal dysfunction preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0186] Rifaximin tablets were dissolved in acetone until 200 mg of rifaximin was added to 30 g of ointment. Nitroglycerin is also added to the ointment.

Embodiment 2

[0188] By mixing 12.5 g of white petrolatum, lanolin, and distilled water containing 2% nitroglycerin (nitroglycerin ointment, USP 2%; E. Fougera & Co., Melville, N.Y.) with 37.5 g of white petrolatum at room temperature in a laboratory mixing vessel. Vaseline, USP (VASELINE; Chesebrough-Ponds USA Co., Greenwich, Conn.) and 100 mg of rifaximin were mixed to prepare an ointment.

Embodiment 3

[0190] 12.5 g of white petrolatum, lanolin, and distilled water (nitroglycerin ointment, USP 2%; E. Fougera & Co., Melville, N.Y.) containing 2% nitroglycerin with 20 g of 2.5% hydrogenated White petrolatum and light mineral oil for cortisone (hydrocortisone ointment, USP 2.5%; Clay-Park Labs, Inc., Bronx, N.Y.), 100 mg of rifaximin and 17.5 g of white petrolatum, USP (VASELINE; Chesebrough-Ponds USA Co., Greenwich, Conn.) mixing.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compositions and methods for treating rectal disorders.

Description

[0001] related application [0002] This application claims U.S. Provisional Patent Application Serial No. 60 / 781,144, filed March 9, 2006, entitled "Rifaximin Anti-Rectal Dysfunction Preparations," and Serial No. 60 / 791,236, to the benefit of U.S. Provisional Patent Application entitled "Rifaximin Anti-Rectal Dysfunction Formulation," which is hereby incorporated by reference in its entirety. Background technique [0003] In general, anal disorders including anal fissures, anal ulcers, and acute hemorrhoids are common benign conditions of the anal canal that affect individuals of all ages, races, and genders. However, these conditions can present problems for treatment and be inconvenient, even if pain is not required. Individuals with anal fissures or anal ulcers often experience anal pain and bleeding that is more pronounced during and after bowel movements. [0004] Hemorrhoids are specialized vascular areas immediately beneath the anal mucosa. Symptomatic hemorrhoidal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K49/00A01N63/00
CPCA61K9/0031A61K9/02A61K9/0014A61K31/21A61K31/437A61K31/573A61K45/06A61P1/00A61P1/04A61P1/12A61P1/18A61P43/00A61P9/00A61P9/14A61K2300/00A61K31/44C12N15/74
Inventor A·萨夫迪D·泰勒
Owner SALIX PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com